HRP20041071A2 - Methods of treating hepatitis - Google Patents

Methods of treating hepatitis

Info

Publication number
HRP20041071A2
HRP20041071A2 HR20041071A HRP20041071A HRP20041071A2 HR P20041071 A2 HRP20041071 A2 HR P20041071A2 HR 20041071 A HR20041071 A HR 20041071A HR P20041071 A HRP20041071 A HR P20041071A HR P20041071 A2 HRP20041071 A2 HR P20041071A2
Authority
HR
Croatia
Prior art keywords
methods
treating hepatitis
patient
hepatitis
treating
Prior art date
Application number
HR20041071A
Other languages
English (en)
Inventor
B. Otterbein Leo
Augustine
Zuckerbraun Brian
Original Assignee
Yale University University of Pittsburgh of the Commonwealth Syste
M Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University University of Pittsburgh of the Commonwealth Syste, M Of Higher Education filed Critical Yale University University of Pittsburgh of the Commonwealth Syste
Publication of HRP20041071A2 publication Critical patent/HRP20041071A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Saccharide Compounds (AREA)
HR20041071A 2002-05-17 2003-05-16 Methods of treating hepatitis HRP20041071A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38152702P 2002-05-17 2002-05-17
PCT/US2003/015263 WO2003096977A2 (en) 2002-05-17 2003-05-16 Methods of treating hepatitis

Publications (1)

Publication Number Publication Date
HRP20041071A2 true HRP20041071A2 (en) 2005-06-30

Family

ID=29550139

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20041071A HRP20041071A2 (en) 2002-05-17 2003-05-16 Methods of treating hepatitis

Country Status (16)

Country Link
US (4) US20040052866A1 (https=)
EP (1) EP1505990B1 (https=)
JP (1) JP4549847B2 (https=)
CN (1) CN1668314B (https=)
AT (1) ATE521357T1 (https=)
CA (1) CA2485465A1 (https=)
DK (1) DK1505990T3 (https=)
EA (1) EA200401525A1 (https=)
ES (1) ES2372273T3 (https=)
HR (1) HRP20041071A2 (https=)
MX (1) MXPA04011426A (https=)
NO (1) NO20045056L (https=)
PL (1) PL205066B1 (https=)
RS (1) RS99304A (https=)
UA (1) UA83465C2 (https=)
WO (1) WO2003096977A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
MXPA03012031A (es) * 2001-06-21 2005-07-01 Univ Yale El monoxido de carbono mejoraresultados en transplantes de tejido y organo y suprime apoptosis.
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
NZ534912A (en) * 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
RS91004A (sr) 2002-04-15 2007-02-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Postupci za lečenje ileusa
EP1499328B1 (en) * 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
JP4549847B2 (ja) 2002-05-17 2010-09-22 イエール ユニバーシティ 肝炎の治療方法
UA87438C2 (ru) * 2002-06-05 2009-07-27 Йельский Университет Способы лечения или профилактики рака, способ проведения хирургической операции по удалению рака и применения монооксида углерода
CN1674942A (zh) * 2002-06-21 2005-09-28 联邦高等教育系统匹兹堡大学 氧化氮、血红素加氧酶－1和血红素降解产物的药学用途
PL377733A1 (pl) * 2002-11-07 2006-02-06 University Of Pittsburgh Of The Commonwealth System Of Higher Education Leczenie wstrząsu krwotocznego
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
US20040218547A1 (en) 2003-04-30 2004-11-04 Rhodey William George Process modification to maximize benzene production
US20070207993A1 (en) * 2005-12-20 2007-09-06 Alfama - Investigacao E Desenvolvimetno De Productos Farmaceuticos Lda Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
WO2007073006A1 (ja) * 2005-12-22 2007-06-28 Keio University 細胞保護性を有するアミノ酸の増加誘導剤及び増加方法
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
CN102170784A (zh) * 2008-10-03 2011-08-31 夏洛特-梅克伦堡医院管理局D/B/A卡罗莱纳医学中心 使用金属卟啉治疗丙型肝炎感染
CA2763111C (en) 2009-05-27 2019-09-24 Ino Therapeutics Llc Devices and methods for engaging indexed valve and pressurized canister assembly with collar and for linear actuation by plunger assembly into fluid communication with device for regulating drug delivery
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
WO2011002584A1 (en) * 2009-07-02 2011-01-06 The University Of Iowa Research Foundation Treatment of hepatitis c virus infections
EP2699242B1 (en) 2011-04-19 2017-11-01 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
CA2844660A1 (en) 2011-08-09 2013-02-14 Leo E. Otterbein Methods of treating dna damage
JP6457749B2 (ja) * 2013-12-27 2019-01-23 ハウスウェルネスフーズ株式会社 Ｖｃａｍ−１発現抑制剤
TW201618795A (zh) 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
CN108057032B (zh) * 2018-01-30 2020-06-05 中国人民解放军第二军医大学第二附属医院 阿尔维林在制备预防或治疗门脉高压症的药物中的应用
EP3524290A1 (en) * 2018-02-09 2019-08-14 Julius-Maximilians-Universitaet Wuerzburg Method and system for monitoring carbon monoxide (co) administration to ex-vivo fluids

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
JPS5679957A (en) 1979-12-05 1981-06-30 Sogo Seibutsu Igaku Kenkyusho:Kk Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5449665A (en) * 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (de) * 1987-11-23 1989-05-24 Immuno Ag Fermenter zum Zuechten von Zellkulturen
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) * 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
NZ262679A (en) * 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
AU6523194A (en) 1993-03-26 1994-10-24 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
DE4421433C1 (de) 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) * 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
JP3195363B2 (ja) * 1995-06-30 2001-08-06 ザイモジェネティクス，インコーポレイティド Ｐｄｇｆアンタゴニストとしての４−〔２−（ｎ−２−カルボキサミドインドール）アミノエチル〕ベンゼンスルホンアミドまたはスルホニル尿素
US5702325A (en) 1996-01-30 1997-12-30 Icon Health & Fitness, Inc. Cabinet treadmill with handle
ATE228869T1 (de) * 1996-02-27 2002-12-15 Koster Henk W Atmungs-system mit zusätzlicher verabreichung von gas
ES2267141T3 (es) * 1996-04-05 2007-03-01 The General Hospital Corporation Tratamiento de una hemoglobinopatia.
US6069132A (en) * 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
WO1998008523A1 (de) 1996-08-27 1998-03-05 Messer Griesheim Gmbh Wasserstoffhaltiges medikament
ATE358492T1 (de) * 1996-09-27 2007-04-15 Univ Columbia Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US5876604A (en) * 1996-10-24 1999-03-02 Compact Membrane Systems, Inc Method of gasifying or degasifying a liquid
TR200101502T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
US6203991B1 (en) * 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2812197B1 (fr) 2000-07-27 2003-01-03 Air Liquide Sante Int Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
BR0208012A (pt) * 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
US20030068387A1 (en) * 2001-03-30 2003-04-10 Roland Buelow Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1395241B9 (en) * 2001-05-25 2005-06-15 Medtronic, Inc. Implantable medical device with controllable gaseous agent release system
MXPA03012031A (es) 2001-06-21 2005-07-01 Univ Yale El monoxido de carbono mejoraresultados en transplantes de tejido y organo y suprime apoptosis.
US7174178B2 (en) 2001-07-19 2007-02-06 Intel Corporation Deriving a more accurate estimate from prediction data in closed loop transmit diversity modes
NZ534912A (en) * 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
BRPI0307673A2 (pt) * 2002-02-13 2016-11-08 Beth Israel Hospital métodos de tratar doença vascular.
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
RS91004A (sr) * 2002-04-15 2007-02-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Postupci za lečenje ileusa
EP1499328B1 (en) * 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
JP2005532314A (ja) * 2002-05-09 2005-10-27 イエール ユニバーシティ 生物マーカーおよび治療剤としての一酸化炭素
JP4549847B2 (ja) 2002-05-17 2010-09-22 イエール ユニバーシティ 肝炎の治療方法
UA87438C2 (ru) * 2002-06-05 2009-07-27 Йельский Университет Способы лечения или профилактики рака, способ проведения хирургической операции по удалению рака и применения монооксида углерода
CN1674942A (zh) * 2002-06-21 2005-09-28 联邦高等教育系统匹兹堡大学 氧化氮、血红素加氧酶－1和血红素降解产物的药学用途
DE10230165A1 (de) 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
PL377733A1 (pl) * 2002-11-07 2006-02-06 University Of Pittsburgh Of The Commonwealth System Of Higher Education Leczenie wstrząsu krwotocznego
WO2005077005A2 (en) 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas

Also Published As

Publication number Publication date
WO2003096977A3 (en) 2004-03-11
CA2485465A1 (en) 2003-11-27
US20040052866A1 (en) 2004-03-18
AU2003234585A1 (en) 2003-12-02
CN1668314A (zh) 2005-09-14
US9522163B2 (en) 2016-12-20
US20130202720A1 (en) 2013-08-08
PL205066B1 (pl) 2010-03-31
RS99304A (sr) 2007-04-10
ATE521357T1 (de) 2011-09-15
UA83465C2 (uk) 2008-07-25
EP1505990A2 (en) 2005-02-16
PL374177A1 (en) 2005-10-03
DK1505990T3 (da) 2011-11-21
MXPA04011426A (es) 2005-10-19
EA200401525A1 (ru) 2006-06-30
JP2005533021A (ja) 2005-11-04
US20120276220A1 (en) 2012-11-01
EP1505990A4 (en) 2008-02-20
CN1668314B (zh) 2011-01-12
EP1505990B1 (en) 2011-08-24
US20140141103A1 (en) 2014-05-22
ES2372273T3 (es) 2012-01-17
NO20045056L (no) 2005-02-16
JP4549847B2 (ja) 2010-09-22
WO2003096977A2 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
HRP20041071A2 (en) Methods of treating hepatitis
UA85041C2 (ru) Способ лечения кишечной непроходимости
UA86570C2 (ru) Способ лечения некротизирующего энтероколита
YU20050003A (sh) Postupak i uređaj za davanje co
EP1670450A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING LEVODOPA AND CARBIDOPA
WO2004043341A3 (en) Treatment for hemorrhagic shock
TW200738270A (en) Method of treating depression using a TNFα antibody
MY142777A (en) Substituted indole-o-glucosides
UA87991C2 (en) Substituted indole-o-glucosides
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
IL173002A (en) Use of calcitonin in the manufacture of oral medication for the prevention or treatment of osteoarthritis
MXPA05009786A (es) Composicion para administracion de hierro para el tratamiento del sindrome de piernas inquietas.
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
TW200509984A (en) Injectable dosage form of flupirtine
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
MXPA05005915A (es) Soluciones de albumina humana terapeutica con baja actividad del activador de precalicreina (pka) y procedimiento de obtencion de las mismas.
PL375354A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
DE60335535D1 (de) Zusammensetzung und verfahren zur abtötung von tumoren
UA36555A (uk) Спосіб відновлення опорної частини зруйнованої кукси зуба

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100507

Year of fee payment: 8

OBST Application withdrawn